Renin-Angiotensin-Aldosterone System (RAAS) Blockers
dc.contributor.advisor | Utidjian, Levon |
dc.contributor.author | Utidjian, Levon |
dc.contributor.other | Children's Hospital of Philadelphia |
dc.date.accessioned | 2024-09-26T13:58:54Z |
dc.date.available | 2024-06-10T19:03:14Z |
dc.date.created | 2021-03-01 |
dc.description | This concept set identifies renin-angiotensin-aldosterone system-blocking medications including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and other agents acting on the renin-angiotensin system. This medication concept set includes the following ingredients: aliskiren, azilsartan, benazepril, candesartan, captopril, cilazapril, enalapril, eprosartan, fosinopril, imidapril, irbesartan, lisinopril, losartan, moexipril, olmesartan, perindopril, quinapril, ramipril, spirapril, telmisartan, trandolapril, valsartan, and zofenopril. It also includes combinations of these ingredients with other antihypertensive medications. This code list was generated by taking the descendants of all the ACE, ARB, and other RAAS agent ingredients of interest, and string matching on the concept_name of the ingredient. Technical Note: This concept set was created when ingredients were required for some sites. It could be enhanced by using SCDF drug levels and taking descendants, making this easier to refresh. This concept set is identical to its predecessor, but it has been expanded to include RxNorm Extension codes in addition to RxNorm codes. |
dc.description.abstract | This broad concept set was intended to identify patients who received angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and other agents acting on the renin-angiotensin system. |
dc.identifier.uri | https://pedsnet.org/metadata/handle/20.500.14642/412.2 |
dc.language.iso | en-US |
dc.provenance | Treatment of Henoch-Schonlein purpura (HSP) Nephritis |
dc.publisher | PEDSnet |
dc.relation.isreferencedby | Stone HK, Mitsnefes M, Dickinson K, et al. 2023. "Clinical course and management of children with IgA vasculitis with nephritis." _Pediatr Nephrol_ 38, 3721�3733. <br>DOI: [10.1007/s00467-023-06023-8](https://doi.org/10.1007/s00467-023-06023-8) |
dc.rights | a CC-BY Attribution 4.0 License. |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ |
dc.subject | Concept Set Development::Content Data Model::PEDSnet Data Model |
dc.subject | Concept Set Development::Concept Set Evaluation::Clinician Reviewed |
dc.subject | Concept Set Development::Concept Set Development Strategy::Broad |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Brand Pack Name |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug Form |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug Form |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug Component |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug Component |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Multiple Ingredients |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Precise Ingredient |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Ingredient |
dc.subject.mesh | Vasoconstrictor |
dc.subject.mesh | Cardiovascular Agent |
dc.subject.other | RxNorm |
dc.subject.other | RxNorm Extension |
dc.title | Renin-Angiotensin-Aldosterone System (RAAS) Blockers |
dspace.entity.type | ConceptSet |
local.quality.status | Needs Refinement |
local.subject.flat | PEDSnet Data Model |
local.subject.flat | Clinician Reviewed |
local.subject.flat | Broad |
local.subject.flat | Brand Pack Name |
local.subject.flat | Semantic Branded Drug |
local.subject.flat | Semantic Clinical Drug |
local.subject.flat | Semantic Branded Drug Form |
local.subject.flat | Semantic Clinical Drug Form |
local.subject.flat | Semantic Branded Drug Component |
local.subject.flat | Semantic Clinical Drug Component |
local.subject.flat | Multiple Ingredients |
local.subject.flat | Precise Ingredient |
local.subject.flat | Ingredient |
relation.isStudyOfConceptSet | 9e8d04a8-d5be-4bd8-a904-c533a7dcd490 |
relation.isStudyOfConceptSet.latestForDiscovery | 9e8d04a8-d5be-4bd8-a904-c533a7dcd490 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- rx_2021_03_ReninAngioTensinAldosteronSystemBlockers_V2.csv
- Size:
- 139.38 KB
- Format:
- Comma-Separated Values